📣 VC round data is live. Check it out!
- Public Comps
- Gradiant
Gradiant Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gradiant and similar public comparables like SRP Groupe, Upexi, Kurashicom, Hour Loop and more.
Gradiant Overview
About Gradiant
Gradiant Corp operates in the retail domain in Korea. Its principal business comprises managing internet-based shopping sites. The company, through its website, sells a range of products including beauty products, fashion wear, household appliances, and food products.
Founded
1997
HQ

Employees
N/A
Website
Financials (FY)
EV
$13M
Valuation Multiples
Start free trialGradiant Financials
Gradiant reported last fiscal year revenue of $2B and EBITDA of $20M.
In the same fiscal year, Gradiant generated $111M in gross profit, $20M in EBITDA, and had net loss of ($24M).
Gradiant P&L
In the most recent fiscal year, Gradiant reported revenue of $2B and EBITDA of $20M.
Gradiant is unprofitable as of last fiscal year, with gross margin of 5%, EBITDA margin of 1%, and net margin of (1%).
Financial data powered by Morningstar, Inc.
Gradiant Stock Performance
Gradiant has current market cap of $92M, and enterprise value of $13M.
Gradiant's stock price is $7.94.
Gradiant has an EPS (earnings per share) of $-2.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $92M | -0.4% | — | — | — | $-2.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGradiant Valuation Multiples
Gradiant trades at 0.0x EV/Revenue multiple, and 0.6x EV/EBITDA.
Gradiant Financial Valuation Multiples
As of May 10, 2026, Gradiant has market cap of $92M and EV of $13M.
Gradiant has a P/E ratio of (3.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gradiant Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Gradiant Margins & Growth Rates
In the most recent fiscal year, Gradiant reported gross margin of 5%, EBITDA margin of 1%, and net margin of (1%).
Gradiant Margins
Gradiant Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Gradiant Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Gradiant Competitors
Gradiant competitors include SRP Groupe, Upexi, Kurashicom, Hour Loop, Answear.com, 09Women, MARX Biotech, Raccoon Holdings, Aromatica Co and Pierce Group.
Most Gradiant public comparables operate across Consumer E-commerce and Horizontal E-commerce.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.1x | 0.1x | (16.8x) | (3.3x) | |||
| 19.3x | 25.2x | (25.2x) | — | |||
| 1.2x | 1.2x | 8.4x | 8.4x | |||
| 0.6x | — | 31.1x | — | |||
| 0.3x | 0.3x | 9.7x | 8.4x | |||
| 2.2x | — | 8.8x | — | |||
| 5.5x | — | 38.2x | — | |||
| 1.5x | 1.5x | 7.0x | — | |||
This data is available for Pro users. Sign up to see all Gradiant competitors and their valuation data. Start Free Trial | ||||||
Gradiant Investment Activity
Gradiant has invested in 1 company to date.
Latest investment by Gradiant was on April 23rd 2025. Gradiant invested in Grove Biopharma in their $30M Series A round (EV/Revenue multiple of ).
Latest Investments by Gradiant
| Description | Grove Biopharma is an Australian biotechnology company developing protein-like polymers for peptide drug delivery. Its materials science platform targets chronic inflammation and neurodegeneration diseases like Alzheimer's. Candidates enhance stability and bioavailability of therapeutics. Operating from grovebiopharma.com, it advances preclinical programs for unmet needs. |
| HQ Country | |
| HQ City | Chicago, IL |
| Deal Date | 23 Apr 2025 |
| Round | Series A |
| Raised | $30M |
| Investors | DCVC Bio; Eli Lilly; Gradiant corporation; InVivium Capital; Mansueto Investments; Walder Ventures |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Gradiant investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gradiant
| When was Gradiant founded? | Gradiant was founded in 1997. |
| Where is Gradiant headquartered? | Gradiant is headquartered in South Korea. |
| Is Gradiant publicly listed? | Yes, Gradiant is a public company listed on Korea Exchange. |
| What is the stock symbol of Gradiant? | Gradiant trades under 035080 ticker. |
| When did Gradiant go public? | Gradiant went public in 1999. |
| Who are competitors of Gradiant? | Gradiant main competitors include SRP Groupe, Upexi, Kurashicom, Hour Loop, Answear.com, 09Women, MARX Biotech, Raccoon Holdings, Aromatica Co, Pierce Group. |
| What is the current market cap of Gradiant? | Gradiant's current market cap is $92M. |
| What is the current revenue of Gradiant? | Gradiant's last fiscal year revenue is $2B. |
| What is the current EV/Revenue multiple of Gradiant? | Current revenue multiple of Gradiant is 0.0x. |
| Is Gradiant profitable? | No, Gradiant is not profitable. |
| How many companies Gradiant has acquired to date? | Gradiant hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Gradiant has invested to date? | As of May 2026, Gradiant has invested in 1 company. |
| What was the last Gradiant investment? | On 23rd April 2025 Gradiant invested in Grove Biopharma, participating in a $30M Series A round, alongside DCVC Bio, Eli Lilly, Gradiant corporation, InVivium Capital, Mansueto Investments, and Walder Ventures. |
| In what companies Gradiant invested in? | Gradiant invested in Grove Biopharma. |
See public comps similar to Gradiant
Lists including Gradiant
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
